TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10078713

Group type: EXPERIMENTAL
Intervention: Eptastigmine 20 mg three times daily
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Eptastigmine 15 mg three times daily
Number of subjects: 491

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study: 8545144

Group type: EXPERIMENTAL
Intervention: Ibuprofen (3 x 400 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ibuprofen (3 x 800 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ibuprofen (3 x 400 mg and 3 x 800 mg)
Number of subjects: 24
Study: 1974509

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg once daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Labetalol (200 mg twice daily)
Number of subjects: 61
Study: 6112925

Group type: EXPERIMENTAL
Intervention: Single dose of 1 g cephaloridine injected intravenously at the start of operations
Number of subjects: 405

Group type: COMPARATOR
Intervention: Single dose of 1 g cephaloridine instilled into the incision at the end of operations
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Classification of abdominal operations by contamination
Number of subjects: 405
Study: 31655161

Group type: EXPERIMENTAL
Intervention: tACS at 40 Hz
Number of subjects: 60

Group type: COMPARATOR
Intervention: tACS at 5 Hz
Number of subjects: 60

Group type: COMPARATOR
Intervention: tACS at sensory-motor cortex
Number of subjects: 60
Study: 29070709

Group type: EXPERIMENTAL
Intervention: HP-BEEF diet (124 g protein/d; 60% from beef, 40% from plant sources)
Number of subjects: 17

Group type: COMPARATOR
Intervention: NP-BEEF diet (48 g protein/d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: NP-PLANT diet (100% from plant-based sources)
Number of subjects: 17
Study: 26332304

Group type: EXPERIMENTAL
Intervention: Positive family history (FH)
Number of subjects: 4932

Group type: COMPARATOR
Intervention: Negative family history (FH)
Number of subjects: 4932

Group type: EXPERIMENTAL
Intervention: Overall prostate cancer incidence predictors
Number of subjects: 4932

Group type: EXPERIMENTAL
Intervention: Gleason score ≥7 prostate cancer on biopsy
Number of subjects: 4932

Group type: EXPERIMENTAL
Intervention: Interval prostate cancer diagnosis
Number of subjects: 4932
Study: 25168659

Group type: EXPERIMENTAL
Intervention: Low-dose glimepiride (0.5 mg/day) with sitagliptin
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Low-dose glimepiride (1 mg/day) with sitagliptin
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Low-dose glimepiride (2 mg/day) with sitagliptin
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (high-dose glimepiride)
Number of subjects: 76
Study: 22030323

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 200
Study: 19926054

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) plus intravenous sodium bicarbonate (NaHCO3)
Number of subjects: 10
Study: 17143601

Group type: EXPERIMENTAL
Intervention: 40 mg AZD5438
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 60 mg AZD5438
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg AZD5438
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 14712468

Group type: EXPERIMENTAL
Intervention: 0.5% racemic bupivacaine alone (group A)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.5% racemic bupivacaine with epinephrine (group B)
Number of subjects: 23

Group type: COMPARATOR
Intervention: 0.5% racemic bupivacaine without epinephrine (group A)
Number of subjects: 23
Study: 11335696

Group type: EXPERIMENTAL
Intervention: Patient with left neglect
Number of subjects: 1

Group type: COMPARATOR
Intervention: Healthy age-matched control subjects
Number of subjects: 1
Study: 9744131

Group type: EXPERIMENTAL
Intervention: Buddy condition (mutual support between clinic sessions)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Solo condition (no mutual support)
Number of subjects: 172
Study: 8058981

Group type: EXPERIMENTAL
Intervention: IS-5-MN (100 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3197367

Group type: EXPERIMENTAL
Intervention: triazolam, 1.0 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: triazolam, 1.5 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: morphine, 0.15 mg/kg
Number of subjects: 62

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 62
Study: 31815645

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study: 28598510

Group type: EXPERIMENTAL
Intervention: ticagrelor
Number of subjects: 6792

Group type: COMPARATOR
Intervention: clopidogrel
Number of subjects: 6792
Study: 26518433

Group type: EXPERIMENTAL
Intervention: Gastric Lavage (GL)
Number of subjects: 500

Group type: COMPARATOR
Intervention: No Lavage
Number of subjects: 500
Study: 24417069

Group type: EXPERIMENTAL
Intervention: Ascoril expectorant (Glenmark) at a standard dose
Number of subjects: 16312
Study: 21482606

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontitis treatment before 21 weeks' gestation
Number of subjects: 411

Group type: COMPARATOR
Intervention: Control group (treated after delivery)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Improvement in maternal periodontal health
Number of subjects: 411
Study: 19558681

Group type: COMPARATOR
Intervention: Azoles
Number of subjects: 965

Group type: COMPARATOR
Intervention: Echinocandins
Number of subjects: 965

Group type: COMPARATOR
Intervention: Anidulafungin
Number of subjects: 965
Study: 17676450

Group type: EXPERIMENTAL
Intervention: Endoscopic endonasal trans‐sphenoidal approach (EETSS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Microsurgical endonasal trans‐sphenoidal approach (SMETSS)
Number of subjects: 20
Study: 16280028

Group type: EXPERIMENTAL
Intervention: 5 mg melatonin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 11987005

Group type: EXPERIMENTAL
Intervention: Active spinal cord injured (SCI) males
Number of subjects: 17

Group type: COMPARATOR
Intervention: Able-bodied male controls
Number of subjects: 17
Study: 9568411

Group type: EXPERIMENTAL
Intervention: Laceran 10% urea lotion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Urea-free Laceran lotion base
Number of subjects: 60
Study: 7713825

Group type: EXPERIMENTAL
Intervention: Increased muscle glycogen from 90.3 +/- 6.0 to 124.7 +/- 10.8 mmol/kg wet wt
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Reduced muscle glycogen from 96.2 +/- 6.6 to 53.7 +/- 6.0 mmol/kg
Number of subjects: 12
Study: 2468300

Group type: EXPERIMENTAL
Intervention: Isovolemic hemodilution with 500 mL of 10% hydroxyethyl starch 200
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham dilutions (placebo)
Number of subjects: 24
Study: 193642

Group type: EXPERIMENTAL
Intervention: POCC (procarbazine, 100 mg/m2/day orally, Days 1‐14; vincristine, 2 mg iv, Days 1 and 8; cyclophosphamide, 600 mg/m2 iv, Days 1 and 8; and CCNU, 60 mg/m2 orally, Day 1)
Number of subjects: 23

Group type: COMPARATOR
Intervention: COM (cyclophosphamide, 2000 mg/m2 iv, Day 1; vincristine, 2 mg iv, Day 1; and methotrexate, 30 mg/m2 iv, Day 15)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both chemotherapy programs
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: POCC
Number of subjects: 23
Study: 31915152

Group type: EXPERIMENTAL
Intervention: Higher triglyceride levels
Number of subjects: 494451

Group type: EXPERIMENTAL
Intervention: Higher LDL-cholesterol levels
Number of subjects: 494451

Group type: EXPERIMENTAL
Intervention: Higher body fat and visceral body fat distribution
Number of subjects: 494451

Group type: EXPERIMENTAL
Intervention: Metabolically 'favourable adiposity' phenotype
Number of subjects: 494451
Study: 31286632

Group type: EXPERIMENTAL
Intervention: Positive education and pedometer walking exercise training (PEPWET)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Pedometer walking exercise training (PWET)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Pedometer walking exercise (PWE)
Number of subjects: 150
Study: 27422483

Group type: EXPERIMENTAL
Intervention: Endothelium-in (endo-in)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Endothelium-out (endo-out)
Number of subjects: 18
Study: 25100406

Group type: EXPERIMENTAL
Intervention: Repair (n = 19)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Replacement (n = 21)
Number of subjects: 20
Study: 23714798

Group type: EXPERIMENTAL
Intervention: Prosthetically guided maxillofacial surgery
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (standard preplating technique)
Number of subjects: 7
Study: 21976398

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) with standard-dose glucocorticoids
Number of subjects: 81
Study: 19736028

Group type: EXPERIMENTAL
Intervention: 12% sucrose solution (1cc)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Distilled water (control group)
Number of subjects: 111
Study: 17032876

Group type: EXPERIMENTAL
Intervention: Periventricular WMH (PVWMH)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Deep WMH (DWMH)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Frontal PVWMH
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Smooth PVWMH
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (19 subjects with no or limited WMH)
Number of subjects: 56
Study: 15648991

Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation with PEEP set at 0, 5 and 10 cmH2O
Number of subjects: 42

Group type: COMPARATOR
Intervention: Pressure support ventilation with PEEP set at 0, 5 and 10 cmH2O
Number of subjects: 42
Study: 11798687

Group type: EXPERIMENTAL
Intervention: Xuezhikang 1.2 g/d Bid, p.o
Number of subjects: 91

Group type: COMPARATOR
Intervention: gemfibrozil 1.2 g/d Bid, p.o
Number of subjects: 91
Study: 7781417

Group type: EXPERIMENTAL
Intervention: ECCE (extracapsular cataract extraction)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: ECCE + IOL (ECCE and intraocular lens implantation)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Lensectomy
Number of subjects: 140
Study: 2086165

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg once a day for 7 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 86051

Group type: EXPERIMENTAL
Intervention: 5.7 units/kg of intermediate factor-VIII concentrate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 3.0 units/kg of intermediate factor-VIII concentrate
Number of subjects: 6
Study: 30735680

Group type: EXPERIMENTAL
Intervention: Active ECAT (eye-gaze contingent attention training)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control condition (free interpretation without gaze-contingent feedback)
Number of subjects: 66
Study: 28251618

Group type: EXPERIMENTAL
Intervention: Powered Respiratory Protective Suit (PRPS ensemble)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Polyprotect 12 ensemble
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unprotected (control)
Number of subjects: 30
Study: 24119034

Group type: EXPERIMENTAL
Intervention: Clear corneal vitrectomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard 25-gauge pars plana vitrectomy with corneal incision cataract surgery
Number of subjects: 20
Study: 22373942

Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19304472

Group type: EXPERIMENTAL
Intervention: Dual endothelin receptor antagonists (ERAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective endothelin receptor antagonists (ERAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Various endothelin receptor antagonists (ERAs)
Number of subjects: 0
Study: 17460732

Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of an educational curriculum at school, conducted by trained teachers, including a short video and distribution of booklets to children and parents.
Number of subjects: 11230

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 11230
Study: 16246657

Group type: EXPERIMENTAL
Intervention: Quick Start with contraceptive patch (Group 1, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional initiation (first day of next menses) (Group 2, n=30)
Number of subjects: 60
Study: 11967245

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 43
Study: 9527182

Group type: EXPERIMENTAL
Intervention: Minimally diluted tepid blood cardioplegia (Mini group, n = 19)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard 4:1 diluted tepid blood cardioplegia (4:1 group, n = 18)
Number of subjects: 37
Study: 7884615

Group type: EXPERIMENTAL
Intervention: D-penicillamine therapy (20 mg/kg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: D-penicillamine therapy (20 mg/kg/day) with prednisolone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1978619

Group type: EXPERIMENTAL
Intervention: Formoterol (24 micrograms)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Albuterol (200 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6996472

Group type: EXPERIMENTAL
Intervention: Dextrose
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Potato
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Rice
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bread
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Corn
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: All carbohydrate loads
Number of subjects: 11
Study: 31712337

Group type: EXPERIMENTAL
Intervention: Pain Toolkit and the Back Book
Number of subjects: 0

Group type: COMPARATOR
Intervention: Back Book only
Number of subjects: 0
Study: 28744857

Group type: EXPERIMENTAL
Intervention: Pre-operative intravenous methylprednisolone 125 mg
Number of subjects: 70
Study: 26374625

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg maintenance dose
Number of subjects: 3400

Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg maintenance dose
Number of subjects: 3400

Group type: COMPARATOR
Intervention: Biostable-polymer PtCr-EES
Number of subjects: 3400

Group type: EXPERIMENTAL
Intervention: Biodegradable-polymer BP-BES
Number of subjects: 3400
Study: 23568561

Group type: EXPERIMENTAL
Intervention: 100 kVp protocol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 100 kVp protocol with optimized display preset
Number of subjects: 100

Group type: COMPARATOR
Intervention: 120 kVp protocol
Number of subjects: 100
Study: 20012051

Group type: EXPERIMENTAL
Intervention: Electrical stimulation combined with continuous passive motion (CPM‐ES)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isometric exercise
Number of subjects: 40
Study: 19736157

Group type: EXPERIMENTAL
Intervention: Bivalirudin and provisional GPIIb/IIIa inhibition
Number of subjects: 32

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) and mandatory GPIIb/IIIa
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 32
Study: 17339385

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation
Number of subjects: 192

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 192
Study: 16802195

Group type: EXPERIMENTAL
Intervention: CD4 counts <50 cells/microl
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Depressive symptoms (CES-D >/= 23)
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Age, gender, education, and source of income adjustments
Number of subjects: 1017
Study: 12757072

Group type: EXPERIMENTAL
Intervention: Fluconazole 600 mg/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Itraconazole 600 mg/day
Number of subjects: 35
Study: 10969219

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (1.2 to 2 g bolus)
Number of subjects: 859

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 859
Study: 8889757

Group type: EXPERIMENTAL
Intervention: Simulated altitude at 3,500 m during exercise
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Simulated altitude at moderate levels (> 2,500 m) during exercise
Number of subjects: 7

Group type: COMPARATOR
Intervention: Exercise at all altitude levels
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Altitude effects at 3,500 m
Number of subjects: 7
Study: 1857478

Group type: EXPERIMENTAL
Intervention: Dipyridamole (300 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7036280

Group type: EXPERIMENTAL
Intervention: Five-drug treatment (CMFVP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three-drug treatment (CMF)
Number of subjects: 0
Study: 31759464

Group type: EXPERIMENTAL
Intervention: PATHS curriculum implementation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Positive attitudes towards PATHS
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Positive culture for social-emotional learning (SEL)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Early career teachers
Number of subjects: 28
Study: 28276794

Group type: EXPERIMENTAL
Intervention: Intravenous ribavirin (33 mg/kg followed by 16 mg/kg every 6 hours for 4 days and 8 mg/kg every 8 hours for 3 days) plus standard therapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 73
Study: 25925875

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (80-120 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23664681

Group type: EXPERIMENTAL
Intervention: a-tDCS with 12 cm² electrode size
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: a-tDCS with 24 cm² electrode size
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: a-tDCS with 35 cm² electrode size
Number of subjects: 12
Study: 21349928

Group type: EXPERIMENTAL
Intervention: Indacaterol, 150 μg once daily
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Indacaterol, 300 μg once daily
Number of subjects: 415

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study: 19660021

Group type: EXPERIMENTAL
Intervention: CP-690,550 15 mg BID (CP15)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CP-690,550 30 mg BID (CP30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 60
Study: 17898337

Group type: EXPERIMENTAL
Intervention: Quetiapine at a dose of 50 mg at bedtime
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Lowering the dosages of antiparkinsonian medications
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Restoration of dopamine agonist dosage
Number of subjects: 1
Study: 15172869

Group type: EXPERIMENTAL
Intervention: Fast-absorbing polyglactin 910
Number of subjects: 1361
Study: 11499564

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 1-g i.v. for three days at months 1, 3, and 5, plus oral prednisone (0.5 mg/kg every other day for six months)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 86
Study: 11360502

Group type: EXPERIMENTAL
Intervention: 1 g intravenous ceftriaxone once a day (group A)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: 3 g intravenous cefotaxime three times a day (group B)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: 2.25 g intravenous cefuroxime three times a day (group C)
Number of subjects: 197
Study: 7869314

Group type: EXPERIMENTAL
Intervention: sulfasalazine treatment
Number of subjects: 84

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 84
Study: 3365292

Group type: EXPERIMENTAL
Intervention: 150 mg zinc/day
Number of subjects: 47
Study: 30289392

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) administered at 1 mg/kg via subcutaneous injection twice a day between days 1 and 7
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 100
Study: 27666953

Group type: EXPERIMENTAL
Intervention: Newly designed work uniform
Number of subjects: 568

Group type: COMPARATOR
Intervention: Commercially available trade uniform
Number of subjects: 568
Study: 25810045

Group type: EXPERIMENTAL
Intervention: Intralesional botulinum toxin type A (BTA) 5 IU/cm(3) repeated every 8 weeks for three sessions (group B)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intralesional corticosteroid therapy repeated every 4 weeks for six sessions (group A)
Number of subjects: 24
Study: 23677811

Group type: EXPERIMENTAL
Intervention: 400 mg ESL (to-be-marketed formulation)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 800 mg ESL (to-be-marketed formulation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 400 mg ESL (marketed formulation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 800 mg ESL (marketed formulation)
Number of subjects: 40
Study: 21367950

Group type: EXPERIMENTAL
Intervention: 60 mg Fe + folic acid (IFA)
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: 30 mg Fe + folic acid + 13 micronutrients (UNIMMAP)
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: UNIMMAP
Number of subjects: 1268

Group type: EXPERIMENTAL
Intervention: IFA
Number of subjects: 1268

Group type: COMPARATOR
Intervention: UNIMMAP or IFA
Number of subjects: 1268

Group type: COMPARATOR
Intervention: Micronutrient intake (both groups)
Number of subjects: 1268

Group type: COMPARATOR
Intervention: Micronutrient intake
Number of subjects: 1268
Study: 19271829

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 690
Study: 17671061

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (20 ppm, weaned to 2 ppm)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo gas
Number of subjects: 99
Study: 15493566

Group type: EXPERIMENTAL
Intervention: Continuous, low-level, topical heat wrap therapy
Number of subjects: 344

Group type: COMPARATOR
Intervention: Acetaminophen (1000 mg)
Number of subjects: 344
Study: 12112107

Group type: EXPERIMENTAL
Intervention: Deprenyl (10mg/day)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study: 10438356

Group type: EXPERIMENTAL
Intervention: valacyclovir
Number of subjects: 310

Group type: COMPARATOR
Intervention: acyclovir
Number of subjects: 310
Study: 8675970

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Naltrexone after desensitization
Number of subjects: 1
Study: 2196306

Group type: EXPERIMENTAL
Intervention: High-expectancy condition
Number of subjects: 63
Study: 346315

Group type: EXPERIMENTAL
Intervention: Halcinonide solution (0.1%)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27